Immunocore has a sip with USD140m private...Immunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline. more ➔
biotech, consumer health, GSK, Haleon, IPO, listing, London, pharma, split, stock exchange GSK splits off consumer health as Haleon &... GlaxoSmithKline (GSK), one of the UKs large pharma player, has voted to spin-off its consumer healthcare business into a new company called Haleon. Shareholders gave the go-ahead for GSK … more ➔
Polpharma Biologics Announces EMA Acceptan... European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS). more ➔
Agomab extenses Series B with USD40m Bring... Agomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount … more ➔
Spatial Biology Company Navinci (Olink) cl... Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round … more ➔
ADC, cancer, Chris Martin, Lausanne, orphan, Sobi, Swedish, Zynlonta Swedish SOBI awarded rights to market Zynl...In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US. more ➔
bioeconomy, biosyntia, bonn, brandkamp, circular, denmark, ECBF, financing, fund ECBF joins Novo Seeds and Sofinnova Partne...The European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused … more ➔
Lonza invests CHF500m in Large-Scale Facil... Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m. more ➔
Evotec, Boehringer Ingelheim, and bioMéri...Evotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a €40m joint venture to fight Antimicrobial Resistance (AMR). more ➔
Urovant Sciences cashes in $75m in licence...French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences drug vibegron for the treatment of overactive bladder in Europe. more ➔
